At Idera, we are driven by what matters most: patients.

Improving the lives of patients is our target, specifically those patients with hard to treat cancers. Despite advances in immunotherapy and targeted therapies, there remains a large, unmet medical need for life-altering and life-saving treatments. We believe that immune activation through our Toll-like receptor 9 (TLR9) agonist can benefit patients and clinicians in their efforts to combat these and other advanced cancers.